Overview

Dose-Dense Induction/Neoadjuvant Chemotherapy in Locally Advanced Non-Small Cell Lung Cancer

Status:
Terminated
Trial end date:
2010-01-01
Target enrollment:
Participant gender:
Summary
Dose-dense chemotherapy is a chemotherapy treatment plan in which drugs are given with less time between treatments than in standard chemotherapy. The two chemotherapy drugs used in this study, docetaxel and cisplatin, are approved for the treatment of lung cancer when given every 21 days. This study is exploring the response to chemotherapy when these drugs are given every 14 days. In addition, genetic tests will be performed on pre-treatment specimens to identify signatures that may predict chemotherapy sensitivity or resistance.
Phase:
Phase 2
Details
Lead Sponsor:
Duke University
Collaborator:
Sanofi
Treatments:
Cisplatin
Docetaxel